Severe arthritis and tenosynovitis caused by immune checkpoint blockade therapy with pembrolizumab (anti-PD-1 antibody)
Identifieur interne : 000391 ( Pmc/Checkpoint ); précédent : 000390; suivant : 000392Severe arthritis and tenosynovitis caused by immune checkpoint blockade therapy with pembrolizumab (anti-PD-1 antibody)
Auteurs : Aprajita Jagpal ; Gagandeep Choudhary ; Jad Chokr [Liban]Source :
- Proceedings (Baylor University. Medical Center) [ 0899-8280 ] ; 2019.
Abstract
Pembrolizumab, a monoclonal antibody against the immune checkpoint receptor–programmed cell death protein 1, has proven clinical efficacy in melanoma and other solid tumors. It increases the body’s immune response against the tumor cells. However, because of an uninhibited immune system, immune-mediated adverse effects can arise. Though most adverse effects from pembrolizumab involve the gastrointestinal tract, skin, and endocrine system, rheumatologic manifestations are not very well defined. We describe two cases of severe inflammatory arthritis and tenosynovitis, which are rare adverse effects of pembrolizumab. Increased awareness of this manifestation is imperative to establish the diagnosis and initiate timely treatment.
Url:
DOI: 10.1080/08998280.2019.1588654
PubMed: 31384207
PubMed Central: 6650205
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:6650205Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Severe arthritis and tenosynovitis caused by immune checkpoint blockade therapy with pembrolizumab (anti-PD-1 antibody)</title>
<author><name sortKey="Jagpal, Aprajita" sort="Jagpal, Aprajita" uniqKey="Jagpal A" first="Aprajita" last="Jagpal">Aprajita Jagpal</name>
<affiliation><nlm:aff id="AF0001"><institution>Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham</institution>
BirminghamAlabama</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Choudhary, Gagandeep" sort="Choudhary, Gagandeep" uniqKey="Choudhary G" first="Gagandeep" last="Choudhary">Gagandeep Choudhary</name>
<affiliation><nlm:aff id="AF0002"><institution>Department of Radiology, University of Alabama at Birmingham</institution>
BirminghamAlabama</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Chokr, Jad" sort="Chokr, Jad" uniqKey="Chokr J" first="Jad" last="Chokr">Jad Chokr</name>
<affiliation wicri:level="1"><nlm:aff id="AF0003"><institution>Department of Radiology, Clemenceau Medical Center, affiliated with Johns Hopkins</institution>
Beirut<country>Lebanon</country>
</nlm:aff>
<country xml:lang="fr">Liban</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">31384207</idno>
<idno type="pmc">6650205</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650205</idno>
<idno type="RBID">PMC:6650205</idno>
<idno type="doi">10.1080/08998280.2019.1588654</idno>
<date when="2019">2019</date>
<idno type="wicri:Area/Pmc/Corpus">000271</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000271</idno>
<idno type="wicri:Area/Pmc/Curation">000271</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000271</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000391</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000391</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Severe arthritis and tenosynovitis caused by immune checkpoint blockade therapy with pembrolizumab (anti-PD-1 antibody)</title>
<author><name sortKey="Jagpal, Aprajita" sort="Jagpal, Aprajita" uniqKey="Jagpal A" first="Aprajita" last="Jagpal">Aprajita Jagpal</name>
<affiliation><nlm:aff id="AF0001"><institution>Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham</institution>
BirminghamAlabama</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Choudhary, Gagandeep" sort="Choudhary, Gagandeep" uniqKey="Choudhary G" first="Gagandeep" last="Choudhary">Gagandeep Choudhary</name>
<affiliation><nlm:aff id="AF0002"><institution>Department of Radiology, University of Alabama at Birmingham</institution>
BirminghamAlabama</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Chokr, Jad" sort="Chokr, Jad" uniqKey="Chokr J" first="Jad" last="Chokr">Jad Chokr</name>
<affiliation wicri:level="1"><nlm:aff id="AF0003"><institution>Department of Radiology, Clemenceau Medical Center, affiliated with Johns Hopkins</institution>
Beirut<country>Lebanon</country>
</nlm:aff>
<country xml:lang="fr">Liban</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Proceedings (Baylor University. Medical Center)</title>
<idno type="ISSN">0899-8280</idno>
<idno type="eISSN">1525-3252</idno>
<imprint><date when="2019">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><title>Abstract</title>
<p>Pembrolizumab, a monoclonal antibody against the immune checkpoint receptor–programmed cell death protein 1, has proven clinical efficacy in melanoma and other solid tumors. It increases the body’s immune response against the tumor cells. However, because of an uninhibited immune system, immune-mediated adverse effects can arise. Though most adverse effects from pembrolizumab involve the gastrointestinal tract, skin, and endocrine system, rheumatologic manifestations are not very well defined. We describe two cases of severe inflammatory arthritis and tenosynovitis, which are rare adverse effects of pembrolizumab. Increased awareness of this manifestation is imperative to establish the diagnosis and initiate timely treatment.</p>
</div>
</front>
</TEI>
<pmc article-type="case-report"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Proc (Bayl Univ Med Cent)</journal-id>
<journal-id journal-id-type="iso-abbrev">Proc (Bayl Univ Med Cent)</journal-id>
<journal-id journal-id-type="publisher-id">UBMC</journal-id>
<journal-id journal-id-type="publisher-id">ubmc20</journal-id>
<journal-title-group><journal-title>Proceedings (Baylor University. Medical Center)</journal-title>
</journal-title-group>
<issn pub-type="ppub">0899-8280</issn>
<issn pub-type="epub">1525-3252</issn>
<publisher><publisher-name>Taylor & Francis</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">31384207</article-id>
<article-id pub-id-type="pmc">6650205</article-id>
<article-id pub-id-type="doi">10.1080/08998280.2019.1588654</article-id>
<article-id pub-id-type="publisher-id">1588654</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Case Reports</subject>
</subj-group>
</article-categories>
<title-group><article-title>Severe arthritis and tenosynovitis caused by immune checkpoint blockade therapy with pembrolizumab (anti-PD-1 antibody)</article-title>
<alt-title alt-title-type="running-authors">Arthritis and Tenosynovitis Caused by Pembrolizumab</alt-title>
<alt-title alt-title-type="running-title">Baylor University Medical Center Proceedings</alt-title>
</title-group>
<contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0056-3407</contrib-id>
<name><surname>Jagpal</surname>
<given-names>Aprajita</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="AF0001"><sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3261-1979</contrib-id>
<name><surname>Choudhary</surname>
<given-names>Gagandeep</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="AF0002"><sup>b</sup>
</xref>
</contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2478-9195</contrib-id>
<name><surname>Chokr</surname>
<given-names>Jad</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="AF0003"><sup>c</sup>
</xref>
<xref ref-type="corresp" rid="AN0001"></xref>
</contrib>
<aff id="AF0001"><label>a</label>
<institution>Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham</institution>
BirminghamAlabama</aff>
<aff id="AF0002"><label>b</label>
<institution>Department of Radiology, University of Alabama at Birmingham</institution>
BirminghamAlabama</aff>
<aff id="AF0003"><label>c</label>
<institution>Department of Radiology, Clemenceau Medical Center, affiliated with Johns Hopkins</institution>
Beirut<country>Lebanon</country>
</aff>
</contrib-group>
<author-notes><fn id="AUFN1"><p>Color versions of one or more of the figures in this article can be found online at <ext-link ext-link-type="uri" xlink:href="http://www.tandfonline.com/ubmc">www.tandfonline.com/ubmc</ext-link>
.</p>
</fn>
<corresp id="AN0001"><bold>Corresponding author:</bold>
Jad Chokr, MD,<institution>Clemenceau Medical Center</institution>
<addr-line>Clemenceau St.</addr-line>
Beirut 11-2555<country>Lebanon</country>
(e-mail:<email>jad_1986@hotmail.com</email>
)</corresp>
</author-notes>
<pub-date pub-type="collection"><month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub"><day>14</day>
<month>5</month>
<year>2019</year>
</pub-date>
<volume>32</volume>
<issue>3</issue>
<fpage seq="28">419</fpage>
<lpage>421</lpage>
<history><date date-type="received"><day>4</day>
<month>11</month>
<year>2018</year>
</date>
<date date-type="rev-recd"><day>22</day>
<month>2</month>
<year>2019</year>
</date>
<date date-type="accepted"><day>26</day>
<month>2</month>
<year>2019</year>
</date>
</history>
<permissions><copyright-statement>Copyright © 2019 Baylor University Medical Center</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Baylor University Medical Center</copyright-holder>
</permissions>
<self-uri content-type="pdf" xlink:href="ubmc-32-03-1588654.pdf"></self-uri>
<abstract><title>Abstract</title>
<p>Pembrolizumab, a monoclonal antibody against the immune checkpoint receptor–programmed cell death protein 1, has proven clinical efficacy in melanoma and other solid tumors. It increases the body’s immune response against the tumor cells. However, because of an uninhibited immune system, immune-mediated adverse effects can arise. Though most adverse effects from pembrolizumab involve the gastrointestinal tract, skin, and endocrine system, rheumatologic manifestations are not very well defined. We describe two cases of severe inflammatory arthritis and tenosynovitis, which are rare adverse effects of pembrolizumab. Increased awareness of this manifestation is imperative to establish the diagnosis and initiate timely treatment.</p>
</abstract>
<kwd-group kwd-group-type="author"><title>Keywords</title>
<kwd>Arthritis</kwd>
<kwd>checkpoint blockade</kwd>
<kwd>immune checkpoint inhibitors</kwd>
<kwd>pembrolizumab</kwd>
</kwd-group>
<counts><fig-count count="2"></fig-count>
<table-count count="0"></table-count>
<page-count count="4"></page-count>
<word-count count="1273"></word-count>
</counts>
</article-meta>
</front>
</pmc>
<affiliations><list><country><li>Liban</li>
</country>
</list>
<tree><noCountry><name sortKey="Choudhary, Gagandeep" sort="Choudhary, Gagandeep" uniqKey="Choudhary G" first="Gagandeep" last="Choudhary">Gagandeep Choudhary</name>
<name sortKey="Jagpal, Aprajita" sort="Jagpal, Aprajita" uniqKey="Jagpal A" first="Aprajita" last="Jagpal">Aprajita Jagpal</name>
</noCountry>
<country name="Liban"><noRegion><name sortKey="Chokr, Jad" sort="Chokr, Jad" uniqKey="Chokr J" first="Jad" last="Chokr">Jad Chokr</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000391 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 000391 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Pmc |étape= Checkpoint |type= RBID |clé= PMC:6650205 |texte= Severe arthritis and tenosynovitis caused by immune checkpoint blockade therapy with pembrolizumab (anti-PD-1 antibody) }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:31384207" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a ChloroquineV1
This area was generated with Dilib version V0.6.33. |